ACELLULAR AND "LOW" PERTUSSIS VACCINES: ADVERSE EVENTS AND THE ROLE OF MUTATIONS

dc.creatorHigashi, HG
dc.creatorLuna, E
dc.creatorPrecioso, AR
dc.creatorVilela, M
dc.creatorKubrusly, FS
dc.creatorDias, WO
dc.creatorRaw, I
dc.date2009
dc.dateMAY-JUN
dc.date2014-07-30T13:43:23Z
dc.date2015-11-26T16:33:21Z
dc.date2014-07-30T13:43:23Z
dc.date2015-11-26T16:33:21Z
dc.date.accessioned2018-03-28T23:15:11Z
dc.date.available2018-03-28T23:15:11Z
dc.identifierRevista Do Instituto De Medicina Tropical De Sao Paulo. Inst Medicina Tropical Sao Paulo, v. 51, n. 3, n. 131, n. 134, 2009.
dc.identifier0036-4665
dc.identifierWOS:000267294300002
dc.identifier10.1590/S0036-46652009000300002
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/54091
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/54091
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1270826
dc.descriptionObjective: to discuss the current PAHO recommendation that does not support the substitution of traditional cellular DTP vaccine by acellular DTP, and the role of mutations, in humans, as the main cause of rare adverse events, such as epileptic-like convulsions, triggered by pertussis vaccine. Data review: the main components related to toxic effects of cellular pertussis vaccines are the lipopolysaccharide of bacterial cell wall and pertussis toxin. The removal of part of lipopolysaccharide layer has allowed the creation of a safer cellular pertussis vaccine, with costs comparable to the traditional cellular vaccine, and which may be a substitute for the acellular vaccine. Conclusion: The new methodology introduced by Instituto Butantan allows for the development of a new safer pertussis vaccine with low LPS content (Plow), and the use of the lipopolysaccharide obtained in the process in the production of monophosphoryl lipid A. This component has shown potent adjuvant effect when administered together with influenza inactivated vaccine, making possible to reduce the antigen dose, enhancing the production capacity and lowering costs.
dc.description51
dc.description3
dc.description131
dc.description134
dc.languageen
dc.publisherInst Medicina Tropical Sao Paulo
dc.publisherSao Paulo
dc.publisherBrasil
dc.relationRevista Do Instituto De Medicina Tropical De Sao Paulo
dc.relationRev. Inst. Med. Trop. Sao Paulo
dc.rightsaberto
dc.sourceWeb of Science
dc.subjectPertussis vaccine
dc.subjectVaccine adverse events
dc.subjectAcellular pertussis vaccine
dc.subjectLow pertussis vaccine
dc.subjectEncephalopathy
dc.subjectVaccination
dc.subjectAutism
dc.titleACELLULAR AND "LOW" PERTUSSIS VACCINES: ADVERSE EVENTS AND THE ROLE OF MUTATIONS
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución